202 related articles for article (PubMed ID: 35524225)
1. The prognostic value of weight loss during radiotherapy among patients with nasopharyngeal carcinoma: a large-scale cohort study.
Jin YN; Xia TL; Mai DM; Yao JJ; Jiang C; He WZ; Xia LP
BMC Cancer; 2022 May; 22(1):505. PubMed ID: 35524225
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
Liang SB; Zhang N; Chen DM; Yang XL; Chen BH; Zhao H; Lu RL; Chen Y; Fu LW
Radiother Oncol; 2019 Mar; 132():223-229. PubMed ID: 30366725
[TBL] [Abstract][Full Text] [Related]
3. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status.
Peng H; Chen L; Zhang Y; Guo R; Li WF; Mao YP; Tan LL; Sun Y; Zhang F; Liu LZ; Tian L; Lin AH; Ma J
Oncotarget; 2016 Apr; 7(17):24208-16. PubMed ID: 27008701
[TBL] [Abstract][Full Text] [Related]
4. Plasma Epstein-Barr Virus MicroRNA BART8-3p as a Diagnostic and Prognostic Biomarker in Nasopharyngeal Carcinoma.
Lin C; Lin K; Zhang B; Su Y; Guo Q; Lu T; Xu Y; Lin S; Zong J; Pan J
Oncologist; 2022 Apr; 27(4):e340-e349. PubMed ID: 35380720
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and prognostic value of pre-retreatment plasma epstein-barr virus DNA in locoregional recurrent nasopharyngeal carcinoma.
Liu MZ; Fang SG; Huang W; Wang HY; Tian YM; Huang RD; Sun Z; Zhao C; Lu TX; Huang Y; Han F
Cancer Med; 2019 Aug; 8(10):4633-4643. PubMed ID: 31268626
[TBL] [Abstract][Full Text] [Related]
6. Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma.
Chen FP; Luo YS; Chen K; Li JY; Huo LQ; Shi L; Ou-Yang Y; Cao XP
Eur J Cancer; 2021 Jul; 151():63-71. PubMed ID: 33964573
[TBL] [Abstract][Full Text] [Related]
7. Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.
Zhang L; Tang LQ; Chen QY; Liu H; Guo SS; Liu LT; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Shao JY; Sun Y; Ma J; Hong MH; Mai HQ
Oncotarget; 2016 Feb; 7(5):6221-30. PubMed ID: 26716900
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Correlations between ABO Blood Group and Pre-Treatment Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy.
Peng H; Chen L; Li WF; Zhang Y; Liu LZ; Tian L; Lin AH; Sun Y; Ma J
PLoS One; 2016; 11(11):e0166194. PubMed ID: 27835689
[TBL] [Abstract][Full Text] [Related]
9. The value of integrating tumor volume and plasma Epstein-Barr virus DNA load during sequential chemoradiotherapy for prognostic prediction and therapeutic guidance in high-risk locoregionally advanced nasopharyngeal carcinoma.
Wang G; Dong Z; Huang C; Du X; Chen L; Li K; Guo R; Tang L; Ma J
Oral Oncol; 2023 Oct; 145():106500. PubMed ID: 37467683
[TBL] [Abstract][Full Text] [Related]
10. Survival impact of radiotherapy interruption in nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis.
Yao JJ; Zhang F; Gao TS; Zhang WJ; Lawrence WR; Zhu BT; Zhou GQ; Ma J; Wang SY; Sun Y
Radiother Oncol; 2019 Mar; 132():178-187. PubMed ID: 30448002
[TBL] [Abstract][Full Text] [Related]
11. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
[TBL] [Abstract][Full Text] [Related]
12. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
[TBL] [Abstract][Full Text] [Related]
13. Spontaneous remission of residual post-therapy plasma Epstein-Barr virus DNA and its prognostic implication in nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis.
Zhang Y; Tang LL; Li YQ; Liu X; Liu Q; Ma J
Int J Cancer; 2019 May; 144(9):2313-2319. PubMed ID: 30485420
[TBL] [Abstract][Full Text] [Related]
14. Elevated plasma fibrinogen level shows superior prognostic value than Epstein-Barr virus DNA load for stage IVA/B nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy era.
Lan M; Chen C; Huang Y; Mao M; Han F; Liao J; Deng M; Duan Z; Zheng L; Wu S; Lu T; Jian Y
Oncotarget; 2016 Jul; 7(29):46242-46252. PubMed ID: 27323828
[TBL] [Abstract][Full Text] [Related]
15. Tumor residue in patients with stage II-IVA nasopharyngeal carcinoma who received intensity-modulated radiation therapy: development and validation of a prediction nomogram integrating postradiotherapy plasma Epstein-Barr virus deoxyribonucleic acid, clinical stage, and radiotherapy dose.
Huang YY; Zhou JY; Zhan ZJ; Ke LR; Xia WX; Cao X; Cai ZC; Deng Y; Chen X; Zhang LL; Huang HY; Guo X; Lv X
BMC Cancer; 2023 May; 23(1):410. PubMed ID: 37149594
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Plasma Epstein-Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era.
Chen WH; Tang LQ; Guo SS; Chen QY; Zhang L; Liu LT; Qian CN; Guo X; Xie D; Zeng MS; Mai HQ
Medicine (Baltimore); 2016 Feb; 95(5):e2642. PubMed ID: 26844482
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ
Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939
[TBL] [Abstract][Full Text] [Related]
18. Combined prognostic value of pretreatment anemia and cervical node necrosis in patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: A large-scale retrospective study.
Zhang LL; Zhou GQ; Li YY; Tang LL; Mao YP; Lin AH; Ma J; Qi ZY; Sun Y
Cancer Med; 2017 Dec; 6(12):2822-2831. PubMed ID: 29034992
[TBL] [Abstract][Full Text] [Related]
19. Prognostic effect of residual plasma Epstein-Barr viral DNA after induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma.
Zheng H; Zhou P; Wang J; Yu YF; Zhou R; Lin Q; Wu SG
Cancer Med; 2023 Jul; 12(14):14979-14987. PubMed ID: 37212447
[TBL] [Abstract][Full Text] [Related]
20. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
